$GILD Recent Headlines Gilead says its drug gives

New Post Public Reply Private Reply Replies (0) Message Board

May 22, 2014 at 10:22 AM

$GILD Recent Headlines

Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead shares to resume trade at 4:30 Eastern 4:09 p.m. April 22, 2014 - Laura Mandaro
Gilead shares are halted 4:03 p.m. April 22, 2014 - Laura Mandaro
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com

Chimerix, Inc. (CMRX) Gains: Stock Up 13.9% - Tale of the Tape 8:44 a.m. Today - Zacks.com
Two Biotechs Mastering Their Domains 8:08 a.m. Today - Barrons.com
Making The Call: Vertex's Cystic Fibrosis Trials Will Succeed. Here's Why. 7:00 a.m. Today - TheStreet.com
Despite Data Thefts, the Password Endures 10:25 p.m. May 21, 2014 - The Wall Street Journal Interactive Edition
Data on Novartis' Ultibro Breezhaler - Analyst Blog 6:30 p.m. May 21, 2014 - Zacks.com
Data on Novartis' Ultibro Breezhaler - Analyst Blog 6:30 p.m. May 21, 2014 - Zacks.com
Top 5 Hedge Fund Net Buys 5:24 p.m. May 21, 2014 - GuruFocus.com
Intercept Sinks on Cholesterol Issue - Analyst Blog 5:12 p.m. May 21, 2014 - Zacks.com
Additional Data on InterMune's Esbriet - Analyst Blog 5:05 p.m. May 21, 2014 - Zacks.com
Dendreon Up on Provenge Data - Analyst Blog 4:40 p.m. May 21, 2014 - Zacks.com
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog 4:30 p.m. May 21, 2014 - Zacks.com
Myriad Genetics Unveils Positive Prolaris Data - Analyst Blog 3:10 p.m. May 21, 2014 - Zacks.com
Gilead's GS-5806 Encourages - Analyst Blog 11:50 a.m. May 21, 2014 - Zacks.com
Celgene Inks Licensing Deal with AADi - Analyst Blog 11:30 a.m. May 21, 2014 - Zacks.com
Insmed (INSM) in Focus: Stock Moves 6.7% Higher - Tale of the Tape 9:18 a.m. May 21, 2014 - Zacks.com
Dendreon Corp. (DNDN) Catches Eye: Stock Up 8% - Tale of the Tape 8:44 a.m. May 21, 2014 - Zacks.com
Auspex Pharmaceuticals (ASPX) Jumps: Stock Rises 9.5% - Tale of the Tape 8:30 a.m. May 21, 2014 - Zacks.com
Invest In AbbVie's New Blockbuster Drug 7:35 a.m. May 21, 2014 - Seeking Alpha
U.S. insurers get indigestion from high drug prices 7:34 a.m. May 21, 2014 - Seeking Alpha
Gilead RSV drug succeeds in Phase 2 trial 6:48 p.m. May 20, 2014 - Seeking Alpha

Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma 12:37 p.m. May 6, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. May 2, 2014 - PR Newswire - PRF
Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors 9:00 a.m. April 30, 2014 - PR Newswire - PRF
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver 9:31 a.m. April 29, 2014 - PR Newswire - PRF
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal 1:50 p.m. April 25, 2014 - BusinessWire - BZX
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Gilead Sciences Announces First Quarter 2014 Financial Results 4:03 p.m. April 22, 2014 - BusinessWire - BZX
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA 4:30 p.m. April 21, 2014 - BusinessWire - BZX
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...